Shubham Singh has been a journalist since 2018, covering business and consumer technology for leading media organizations such as India Today, CNBC-TV18, Zee News, and others. As a Reporter for Medtech Insight, he covers policy, regulation, and digital tech. Outside work, Shubham is an avid traveler, foodie, and fitness enthusiast, balancing his schedule with gym sessions, trekking, and OTT binge-watching.
Latest from Shubham Singh
Abbott said Exact Sciences will operate as a subsidiary following the transaction. The acquisition adds a business generating more than $3bn in annual revenue to Abbott’s diagnostics portfolio.
Rising logistics and energy costs linked to disruptions in shipping through the Strait of Hormuz are beginning to ripple through India’s medical device supply chain. Industry leaders warn prolonged instability could raise production costs, strain working capital and disrupt manufacturing schedules.
After its IPO, MiniMed has its first FDA clearance as a public company. The MiniMed Flex – smaller, screenless, and smartphone-controlled – is the product the newly independent diabetes firm needed to shift the conversation from market debut to market execution.
Danaher paid $9.9bn for Masimo. Abbott committed to Exact Sciences. Boston Scientific reached for Penumbra. Medtronic accelerated on multiple fronts. The window medtech spent two years waiting for is open – and the industry is moving through it fast.
The combined entity will employ more than 20,000 people across more than 100 countries, hold close to 3,000 patents, and bring together more than 700 R&D professionals.
Owkin has spun out its diagnostics division as Waiv, raising $33m to scale AI precision testing in oncology. Waiv CEO Meriem Sefta tells Medtech Insight why the diagnostic infrastructure underpinning precision medicine is already broken – and how Waiv intends to fix it.